

****Published June 2016****

MarketVIEW: Seasonal influenza vaccines (CAT: VAMV036)

Product Name	:	MarketVIEW: Seasonal influenza vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + forecast model(s) (.xls)
Therapeutic Area	:	Seasonal influenza vaccines
Publication date	:	June 2016
Catalogue No	:	VAMV036

Background

Annual **influenza** epidemics typically affect 5-15% of the population with mainly upper respiratory tract infections. On a global basis around 3-5 million cases of severe illness are estimated each year with an associated 250,000 – 500,000 deaths (WHO figures). Annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications. Recommended groups for influenza vaccination are usually those most vulnerable and include the elderly, very young and those with underlying chronic diseases. In the US, influenza vaccination recommendations now include every person >6 mos. Influenza vaccines are predominantly of the trivalent inactivated format (TIV) although latest advances include the addition of another B virus strain to form quadrivalent (QIV) vaccines.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of seasonal influenza vaccines across seven major Western and 21 emerging or “rest of world” markets to 2030. The model contains validated volume (mio doses) estimates for all recommended target groups per country based on country specific vaccine coverage rates. Country market values are ascertained by a pricing methodology based upon public/private sector prices for TIVs, QIVs, high dose (HD), LAIV and other forms where the impact of discounting is explored. The analysis contains a detailed US forecast by product type and individual competitor including **Seqirus**' new QIV (Flucelvax). A new methodology is introduced to estimate the adoption of QIV products outside of the key US market with analysis of the UK childhood program. The hypothetical value of further childhood programs is also included.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to seasonal influenza vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published June 2016 (CAT No: VAMV036)

****This product is a summary presentation (.pdf), a forecast model (.xls) and information workbook (.xls)¹

Contents

Author's notes

Executive summary

[SECTION] Seasonal influenza vaccines: key model outputs

Seasonal influenza vaccine(s): predicted volume to 2034 (GLOBAL)

Seasonal influenza vaccine(s): predicted market to 2030 (GLOBAL)

Seasonal influenza vaccine(s): predicted volume to 2034 (USA)

Seasonal influenza vaccine(s): predicted volume to 2034 (EU5+CAN)

Seasonal influenza vaccine(s): predicted volume to 2034 (EU5+ CAN) by country

Seasonal influenza vaccine(s): predicted volume to 2034 (UK) by target group

Seasonal influenza vaccine(s): predicted volume to 2034 (ROW)

Seasonal influenza vaccine(s): predicted market to 2034 (USA)

Seasonal influenza vaccine(s): predicted market to 2034 (EU5+CAN)

Seasonal influenza vaccine(s): market value per country 2014 (ROW)

USA market: forecast by current product type to 2030

USA market: forecast by competitor 2016-2021

Seasonal influenza vaccine(s): adoption of QIVs - 2015 (doses 000s)

Changes from January 2014 forecast/rationale

Potential val/vol of childhood programs for France, Germany, Italy, Spain to 2030

[SECTION] Seasonal influenza: a review of activity/vaccination recommendations in major markets

US: brief review of 2015-2016 season.

Percentage of Visits for Influenza-like Illness (ILI) US. ILINet

2015-2016 season: Latest synopsis (at Week 13 (ending April 2, 2016)

Vaccine effectiveness: US 2015-2016 influenza season

Vaccine effectiveness: US 2005-2015

US influenza seasons 2000 to 2015/16 - vaccine doses distributed

Seasonal influenza vaccines : vaccine product options US (2015/16)

Seasonal influenza vaccines : vaccine format options US (2013/14)

Flu Vaccination Coverage, United States, 2013-15 Influenza Season

US ACIP recommendations - changes for 2015-2017 seasons

United Kingdom: brief review of influenza season 2015/2016

United Kingdom: influenza vaccine coverage rates (2015/2016)

United Kingdom: elements of Flu Plan 2015-2016

¹ Influenza vaccine coverage rates per country per target group

Continued.....

United Kingdom: position on Fluenz Tetra[®] (LAIV)
United Kingdom: numbers vaccinated 2011/12 vs 2012/13 vs 2014/15
United Kingdom: numbers vaccinated: 2014/15 (2 - 4 yrs)
Major EU countries: influenza intensities, spread and virus/subtype
France: influenza vaccination recommendations 2015/16
Germany: influenza vaccination recommendations 2015/16
Italy: influenza vaccination recommendations 2015/16
Spain: influenza vaccination recommendations 2015/16
Seasonal influenza vaccine usage: EU25 (2012/13 season) – highlights
Seasonal influenza vaccine usage: EU25 (2012/13 season) MAP
Major 5EU countries: vaccine procurement/delivery (000s), 2012/13
Influenza vaccine doses distributed per 1000 population
[SECTION] Seasonal influenza vaccines: Update on competitor activity - 2016
Major influenza vaccine suppliers: global sales 2011 - 2015 (\$m)
Major influenza vaccine suppliers: % US sales 2015
US influenza vaccine market per company 2011-2015
US market: competitor production 2000-2015 (doses 000s)
Sanofi Pasteur: key highlights for 2015/2016 season
Sanofi Pasteur – influenza vaccine franchise (US)
Sanofi Pasteur – global influenza vaccine sales (2010 - 2015)
Sanofi Pasteur – US differentiation strategy (2012 - 2015)
Sanofi Pasteur – forecast influenza vaccine US sales (2016 - 2021)
Sanofi Pasteur – is INTANZA successful?
GSK: key highlights for 2015/2016 season
GSK Bio – influenza vaccine franchise (US)
GSK Bio – global influenza vaccine sales (2011 - 2015)
GSK Bio – forecast influenza vaccine US sales (2016 - 2021)
GSK Bio –forecasting QIV UK (public) doses (2016 - 2020)
AZ/MedImmune: key highlights for 2015/2016 season
AZ/MedImmune: key highlights for 2015/2016 season (cont..)
AZ/MedImmune – US influenza vaccine franchise
AZ/MedImmune – global influenza vaccine sales (2011 - 2015)
AZ/MedImmune – forecast influenza vaccine US sales (2016 - 2021)
AZ/MedImmune –forecasting LAIV demand UK (2016 - 2020)
AZ/MedImmune – potential revenues from further childhood programs
Seqirus: key highlights for 2015/2016 season
Seqirus – progress with QIVs
Seqirus – influenza vaccine franchise
Seqirus – 2014 FY results and 2015/2016 HY results
Seqirus – forecast influenza vaccine US sales (2016 - 2021)
Protein Sciences Corporation (3 slides)
Other key marketed seasonal influenza vaccines (global)
[SECTION] Seasonal influenza vaccines: modelling potential demand/commercial value
Countries included in demand forecast model
Populations modelled to 2035
Modelling strategy: segments/countries
Coverage assumptions per country/target group (West)
Coverage assumptions per country/target group (ROW) I – public
Coverage assumptions per country/target group (ROW) II – public

Continued.....

Coverage assumptions per country/target group (ROW) I – private
Coverage assumptions per country/target group (ROW) II – private
Major Western countries: model validations on usage
ROW Countries modelled: summary of schedule/volumes
ROW Countries modelled: summary of schedule/volumes (cont..)
Second dose coverage rates applied
Risk groups
Validating model US volumes - 2014/15
Pricing methodology (TIV, QIV, LAIV, other)
Weighted average pricing methodology
Validating US \$ market value – 2015
The impact of price discounting (US)
The impact of price discounting (UK/EU) and QIVs
QIV use outside of US (Australia)
Forecasting QIVs: global market (excl USA) to 2034
Model caveats and limitations
References/bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~122 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
CHARTS →
Global Val/Vol
USA Val/Vol
West (excl USA) Val/Vol
UK Val/Vol
ROW Val/Vol
QIV adoption
Value summaries →
Global (all) val vol
West excluding USA + ROW QIV val/vol
Hypothetical EU childhood program(s)
Demand analyses →
Grand value ROW (pub & priv)
Grand value WEST (pub & priv)
Weighted average pricing
Pricing summary – TIV
Pricing summary – QIV
Pricing summary – LAIV
Pricing summary – INTANZA
Grand volume ROW (pub & priv)
Grand volume WEST (pub & priv)
Total volume sum (private ROW)
Total volume sum (private West)
Total volume sum (public ROW)
Total volume sum (public West)
Volume summary (infant risk)
Volume summary (2-19 yrs risk)
Volume summary (19-65 yrs risk)
Volume summary (> 65 yrs)



Continued....

Private sector growth rates
Country worksheets (all segments)
USA
Canada
United Kingdom
% vol by type Italy QIV calc
UK program
France
Germany
Italy
Argentina
Australia
Brazil
China
Hong Kong
India
Indonesia
Japan
Macau
Malaysia
Mexico
Mongolia
Nepal
Pakistan
Philippines
Russia
South Korea
Taiwan
Thailand
Turkey
Vietnam
New Zealand
Resources =>>>
Competitor sales and forecasts
US vol by age CDC validation
US historical production
US Val Vol forecast
Sanofi Pasteur sales
Sanofi Pasteur graphs
GSK & AZmed (graphs)
All top suppliers
Country actual vol data (EU)
Country database ROW
Country actual vol data (ROW)
WHO schedules – influenza
Population databases
% private
Risk groups
Back page

Worksheets = >120 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$10,995.00**/ GBP **£7589.00**# (Region license)*
- PRESENTATION OR MODEL ONLY - USD **\$5995.00** (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. WHO Global Action Plan for influenza vaccines. GAP consultation: 12 – 14th July 2011. Available at: http://www.who.int/influenza_vaccines_plan/resources/gap_2011/en/index.html. Accessed May 2016
2. US CDC. Seasonal Influenza Vaccine & Total Doses Distributed. Available at: <http://www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm> Accessed May 2016
3. Sinovac 20-F Statement. Available at: <http://www.sinovac.com/file/File/1436664659.pdf>. Accessed May 2016
4. Petrovax Pharma. Press Release, 2014. Available at: <http://www.petrovax.com> Accessed May 2016
5. Petrovax Pharma. Press Release, 2014. Available at: http://petrovax.com/press_centre/news/812/. Accessed May 2016
6. Centers for Disease Control and Prevention. Estimated influenza illnesses and hospitalizations averted by influenza vaccination - United States, 2014-15 influenza season. Available at: <http://www.cdc.gov/flu/about/disease/2014-15.htm>. Accessed April 2016
7. Centers for Disease Control and Prevention. Health Advisory. Flu Season Begins: Severe Influenza Illness reported. February 1st 2016. Available at: <http://emergency.cdc.gov/han/han00387.asp>. Accessed April 2016
8. US Centres for Disease Control and Prevention. Update – Influenza Activity, United States. 2015-2016 Influenza Season . Available at: http://www.cdc.gov/mmwr/volumes/65/wr/mm6506a3.htm?s_cid=mm6506a3_e. Accessed April 2016
9. US Centres for Disease Control and Prevention. Update – Weekly US Influenza Surveillance Report. Week 13 ending April 2, 2016. Available at: <http://www.cdc.gov/flu/weekly/>. Accessed April 2016
10. US Centres for Disease Control and Prevention. Protection from flu vaccination reduced this season. Available at: <http://www.cdc.gov/media/releases/2015/p0115-flu-vaccination.html>. Accessed April 2016
11. US Centres for Disease Control and Prevention. Flu vaccination nearly 60% effective. Available at: <http://www.cdc.gov/media/releases/2016/flu-vaccine-60-percent.html>. Accessed April 2016
12. Flannery B et al. US Flu VE Network. End-of-season influenza vaccine effectiveness estimates for the 2014-15 season: US Influenza Vaccine Effectiveness (Flu VE) Network Available at: <http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/flu-02-flannery.pdf>. Accessed April 2016
13. US Centres for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness. 2005-15. Available at: <http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm>. Accessed April 2016
14. US Centres for Disease Control and Prevention. Seasonal Influenza Vaccine & Total Doses Distributed. Available at: <http://www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm>. Accessed April 2016
15. Fluzone: Vaccine and influenza market update. Presentation by Phil Hosbach. National influenza Vaccine Summit. Available at: http://www.preventinfluenza.org/NAIIS_2013/NAIIS_12_hosbach-sanofipasteur-update.pdf Accessed April 2016
16. National Early Season Flu Vaccination Coverage, United States, November 2015 Influenza Season. Available at: <http://www.cdc.gov/flu/fluview/nifs-estimates-nov2015.htm>. Accessed April 2016
17. Grohskopf L et al. Influenza division CDC, Proposed Recommendations 2016-2017 season. ACIP meeting, February 24th, 2016
18. Summary* Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—(ACIP)—United States, 2015-16. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm#Groups_Recommended_Vaccination_Timing_Vaccination. Accessed April 2016
19. Summary* Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—(ACIP)—United States, 2013-14. Available at: <http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm>. Accessed April 2016
20. PHE Weekly National Influenza Report. 14 April 2016 – Week 15 report (up to week 14 data)
21. Flu Plan Winter 2015/16. Public Health England. Department of Health. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418038/Flu_Plan_Winter_2015_to_2016.pdf. Accessed April 2016
22. UK Joint Committee on Vaccination and Immunisation (JCVI). Available at: Joint Committee on Vaccination and Immunisation - minutes. (2015). <https://app.box.com/s/iddfb4ppwkmjtjusir2tc/1/2199012147/33352264435/1>. Accessed April 2016
23. UK Department of Health. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/429612/Seasonal_Flu_GP_Patient_Groups_Annual_Report_2014_15.pdf. Accessed April 2016
24. Flunews Europe. Week 14/2016 (4-10 April 2016) Available at: <http://flunewseurope.org/>. Accessed April 2016

25. Seasonal influenza vaccination program. France. Available at: <http://ecdc.europa.eu/en/publications/Report%20Assets/seasonal-vaccination-coverage-in-europe-2012-13/Seasonal-Influenza-Vaccination-Programme-Country-Profile-France.pdf> Accessed April 2016
26. McGuire A et al. Childhood & Adolescent Influenza Vaccination in Europe: A Review of the Evidence. April 2015. Available at: <http://blogs.lse.ac.uk/lseenterprise/files/2015/04/ChildhoodAndAdolescentInfluenzaVaccination.pdf>. Accessed April 2016
27. Seasonal influenza vaccination program. Germany. Available at: <http://ecdc.europa.eu/en/publications/Report%20Assets/seasonal-vaccination-coverage-in-europe-2012-13/Seasonal-Influenza-Vaccination-Programme-Country-Profile-Germany.pdf> Accessed April 2016
28. Seasonal influenza vaccination program. Italy. Available at: <http://ecdc.europa.eu/en/publications/Report%20Assets/seasonal-vaccination-coverage-in-europe-2012-13/Seasonal-Influenza-Vaccination-Programme-Country-Profile-Italy.pdf> Accessed April 2016
29. Seasonal influenza vaccination program. Spain. Available at: <http://ecdc.europa.eu/en/publications/Report%20Assets/seasonal-vaccination-coverage-in-europe-2012-13/Seasonal-Influenza-Vaccination-Programme-Country-Profile-Spain.pdf> Accessed April 2016
30. Paul Erlich Institute. Distributed by 27/11/2015. Available at: <http://www.pei.de/DE/infos/fachkreise/impfungen-impfstoffe/influenza-grippeimpfstoffe-saisonal/influenza-grippeimpfstoffe-node.html>. Accessed April 2016
31. Validaton: Tuppin P et al. Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during the context of pandemic influenza A(H1N1) in 2009. Vaccine 29 (2011) 4632-4637
32. Palache A et al. Seasonal influenza vaccine dose distribution in 195 countries(2004–2013): Little progress in estimated global vaccination coverage. Vaccine 33 (2015) 5598–5605
33. Palache A et al. Seasonal influenza vaccine dose distribution in 195 countries(2004–2013): Little progress in estimated global vaccination coverage. Vaccine 33 (2015) 5598–5605
34. Sanofi Pasteur. Form 20-F. Available at: www.sanofi-aventis.com. Accessed April 2016
35. Sanofi Pasteur presentation. Phil Hosbach. National Adult and Influenza Immunization Summit. 2015
36. Herts NHS. Available at: [http://hertsvalleysccg.nhs.uk/uploads/file/Pharmacy/Local%20Decisions/Intanza%20intradermal%20influenza%20vaccine%20201207\(HMMC\).pdf](http://hertsvalleysccg.nhs.uk/uploads/file/Pharmacy/Local%20Decisions/Intanza%20intradermal%20influenza%20vaccine%20201207(HMMC).pdf). Accessed May 2016
37. Public Health Agency of Canada. Available at: <http://www.phac-aspc.gc.ca/naci-ccni/flu-2015-grippe-eng.php>. Accessed May 2016
38. GSK FY Results 2015. Available at: www.gsk.com Accessed April 2016
39. GSK Corporate Press Release. 16th July 2015. Available at: <https://us.gsk.com/en-us/media/press-releases/2015/gsk-begins-shipping-2015-16-us-flu-vaccines-with-focus-on-customer-needs-volume-and-speed/>. Accessed April 2016
40. US CDC. April 26th 2015. GlaxoSmithKline (GSK) Reports Flu Vaccine Recall.
41. AstraZeneca. FY Results 2015. Available at: <https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/2016/Fourth%20quarter%20and%20Full-Year%20results%202015%20press%20release.pdf> Accessed April 2016
42. Public Health England. Vaccine Update. Issue 235, October 2015
43. AstraZeneca. Flu Summit, 2015. Available at: <http://www.izsummitpartners.org/wp-content/uploads/2015/05/21f-2-Richmond-AstraZeneca-MedImmune-Update.pdf>. Accessed April 2016
44. CSL limited. Half Year Report. 2015-16. Available at: http://www.csl.com.au/docs/472/155/CSL_HYR16%20sec.pdf. Accessed April 2016
45. November 2015. US FDA. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm> Accessed April 2016
46. Protein sciences Corporation. Corporate News Releases. Available at: <http://www.proteinsciences.com/Pub.htm>. Accessed April 2016
47. Flublok Presentation by Protein sciences Corporation. National influenza Vaccine Summit 2015. Available at: <http://www.izsummitpartners.org/wp-content/uploads/2015/05/21g-1-Hachey-Protein-Updated.pdf> Accessed April 2016
48. Flublok Presentation by Protein sciences Corporation. National influenza Vaccine Summit 2015. Available at: <http://www.izsummitpartners.org/wp-content/uploads/2015/05/21g-1-Hachey-Protein-Updated.pdf> Accessed April 2016
49. Herzog C et al. Eleven years of Inflflexal® V—a virosomal adjuvanted influenza vaccine. Vaccine 27 (2009) 4381-4387
50. News article. Flu vaccine shortage set to be resolved this month after health ministry OKs Kaketsuken’s products. Japan times. Oct 22, 2015
51. National Early Season Flu Vaccination Coverage, United States, November 2015 Available at: <http://www.cdc.gov/flu/fluview/nifs-estimates-nov2015.htm>. Accessed April 2016
52. Flu vaccination rates in Canada. Available at: <http://www.statcan.gc.ca/pub/82-624-x/2015001/article/14218-eng.htm>. Accessed April 2016

53. Boder B et al BMC Public Health (2015) 15:618. Available at: <http://www.biomedcentral.com/content/pdf/s12889-015-1970-4.pdf>. Accessed November 2015
54. Trujillo et al Hum Vaccin Immunother. 2013 Jun;9(6):1326-32. doi: 10.4161/hv.23926. Epub 2013 Feb 12
55. Brazil – Ministerio de Saude
56. India – Koul PA et al. Available at: <http://www.journalofdiabetology.org/Pages/Releases/FullTexts/FOURTEENISSUE/SC-5-JOD-13-038.aspx>. Accessed April 2016
57. China – See MS Excel workbook “coverage rates”
58. Australia – See MS Excel workbook “coverage rates”
59. Japan – See MS Excel workbook “coverage rates”
60. Argentina – Argentina. Ministerio de Salud. Influenza vaccination 2012/2013
61. CDC MMWR. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm#Groups_Recommended_Vaccination_Timing_Vaccination. Accessed May 2016
62. US CDC. Available at: <http://www.cdc.gov/flu/protect/children.htm>. Accessed May 2016
63. Stockwell M et al. Text Message Reminders for Second Dose of Influenza Vaccine: A Randomized Controlled Trial. January 2015, VOLUME 135 / ISSUE 1
64. Argentina Ministry of Health Available at: http://www.msal.gob.ar/images/stories/bes/graficos/0000000450cnt-2014-03_lineamientos-gripe-2014-final.pdf. Accessed May 2016
65. US CDC. Available at: <http://www.cdc.gov/flu/fluview/coverage-1415estimates.htm>. Accessed May 2016
66. McKesson. Flumist QIV prebook program. Available at: https://www.flumistquadrivalent.com/hcp/pdf/3191621_McKesson_Prebook_Order_Form.pdf. Accessed May 2016
67. LMC Buying Groups Federation. Available at: <http://www.nwlmcs.org/wp-content/uploads/2014/11/Seasonal-Flu-Vaccine-Offers-2015-16-Final.pdf>. Accessed May 2016
68. Australian Government Bulletin. Available at: <http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/ATAGI-advice-influenza-vaccines-providers#vaccines>. Accessed May 2016

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and “the spiral logo” are UK Registered Trademarks, 2009